12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trial

IF 2.6 3区心理学 Q2 BEHAVIORAL SCIENCES

Behavioural Brain Research Pub Date : 2024-08-08 DOI:10.1016/j.bbr.2024.115191

{"title":"12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trial","authors":"","doi":"10.1016/j.bbr.2024.115191","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Persons with multiple sclerosis (PwMS) suffer from sleep disturbances, fatigue and pain, which can be due, at least in part, to decreased levels of endogenous melatonin. These alterations could exacerbate postural instability, gait disorders and fall risk. Acute effects of exogenous melatonin on physical disorders have been studied in PwMS but its long-term effects on these parameters have not been explored yet in this population. This study aimed to determine the impact of chronic melatonin intake on dynamic postural stability, walking performance and fall risk in PwMS.</p></div><div><h3>Methods</h3><p>This randomized placebo-controlled study included 27 PwMS who were assigned to either melatonin group (MG, n=15) or placebo group (PG, n=12) (3 mg/night for 12 weeks). Dynamic postural balance (force platform), walking performance (locometer) and fall risk (Four Square Step Test) were evaluated pre (T0)- and post (T1)-intervention. Sleep quality (Pittsburgh Sleep Quality Index (PSQI)), fatigue perception (Fatigue Severity Scale (FSS)), neuropathic pain (Neuropathic Pain Questionnaire 4 (DN4)) and quality of life (International Multiple Sclerosis (MS) Quality of Life Questionnaire) were also assessed at T0 and T1.</p></div><div><h3>Results</h3><p>The center of pressure mean velocity decreased in MG compared with PG in the frontal plane (22.98 %, p=0.028). Stride length and walking speed increased in MG comparatively with PG (18.09 %, p=0.036; 9.65 %, p=0.025, respectively). The PSQI (55.89 %, p<0.001), FSS (32.38 %, p=0.003) and DN4 (32.41 %, p=0.035) scores decreased in MG compared with PG.</p></div><div><h3>Conclusion</h3><p>12-week melatonin supplementation can be recommended for managing MS-related gait disorders and dynamic postural imbalance. This therapy may also be prescribed for PwMS due to its anti-fatigue and analgesic effects as well as its benefits on sleep quality.</p></div><div><h3>Clinical registration</h3><p>This study was prospectively recorded in the Pan African Clinical Trial Registry database (PACTR202007465309582) (<span><span>https://pactr.samrc.ac.za/</span><svg><path></path></svg></span>.)</p></div>","PeriodicalId":8823,"journal":{"name":"Behavioural Brain Research","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioural Brain Research","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0166432824003474","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Persons with multiple sclerosis (PwMS) suffer from sleep disturbances, fatigue and pain, which can be due, at least in part, to decreased levels of endogenous melatonin. These alterations could exacerbate postural instability, gait disorders and fall risk. Acute effects of exogenous melatonin on physical disorders have been studied in PwMS but its long-term effects on these parameters have not been explored yet in this population. This study aimed to determine the impact of chronic melatonin intake on dynamic postural stability, walking performance and fall risk in PwMS.

Methods

This randomized placebo-controlled study included 27 PwMS who were assigned to either melatonin group (MG, n=15) or placebo group (PG, n=12) (3 mg/night for 12 weeks). Dynamic postural balance (force platform), walking performance (locometer) and fall risk (Four Square Step Test) were evaluated pre (T0)- and post (T1)-intervention. Sleep quality (Pittsburgh Sleep Quality Index (PSQI)), fatigue perception (Fatigue Severity Scale (FSS)), neuropathic pain (Neuropathic Pain Questionnaire 4 (DN4)) and quality of life (International Multiple Sclerosis (MS) Quality of Life Questionnaire) were also assessed at T0 and T1.

Results

The center of pressure mean velocity decreased in MG compared with PG in the frontal plane (22.98 %, p=0.028). Stride length and walking speed increased in MG comparatively with PG (18.09 %, p=0.036; 9.65 %, p=0.025, respectively). The PSQI (55.89 %, p<0.001), FSS (32.38 %, p=0.003) and DN4 (32.41 %, p=0.035) scores decreased in MG compared with PG.

Conclusion

12-week melatonin supplementation can be recommended for managing MS-related gait disorders and dynamic postural imbalance. This therapy may also be prescribed for PwMS due to its anti-fatigue and analgesic effects as well as its benefits on sleep quality.

Clinical registration

This study was prospectively recorded in the Pan African Clinical Trial Registry database (PACTR202007465309582) (https://pactr.samrc.ac.za/.)

查看原文本刊更多论文

为期12周的褪黑素补充治疗可改善多发性硬化症患者的动态姿势稳定性和行走表现：随机对照试验

背景：多发性硬化症患者（PwMS）患有睡眠障碍、疲劳和疼痛，其原因至少有一部分是内源性褪黑激素水平下降。这些障碍会加剧姿势不稳、步态障碍和跌倒风险。外源性褪黑激素对多发性硬化症相关生理紊乱的急性影响已有研究，但其对这些参数的长期影响尚未在 PwMS 中进行探讨。本研究旨在确定长期摄入褪黑素对 PwMS 的动态姿势稳定性、行走表现和跌倒风险的影响：这项随机安慰剂对照研究包括 27 名 PwMS，他们被分配到褪黑素组（MG，n=15）或安慰剂组（PG，n=12）（3 毫克/晚，12 周）。对干预前（T0）和干预后（T1）的动态姿势平衡（测力平台）、行走能力（定位仪）和跌倒风险（四方步测试）进行评估。在 T0 和 T1 阶段，还对睡眠质量（匹兹堡睡眠质量指数 (PSQI)）、疲劳感（疲劳严重程度量表 (FSS)）、神经性疼痛（神经性疼痛问卷 4 (DN4)）和生活质量（国际多发性硬化症 (MS) 生活质量问卷）进行了评估：结果：与多发性硬化症患者相比，多发性硬化症患者在额面的压力中心平均速度有所下降（22.98%，P=0.028）。与 PG 相比，MG 的步长和步行速度增加了（分别为 18.09%，p=0.036；9.65%，p=0.025）。PSQI（55.89%，P=0.025）：建议长期服用褪黑素来控制与多发性硬化症相关的步态障碍和动态姿势失衡。褪黑素还具有抗疲劳和镇痛作用，并能改善 PwMS 的睡眠质量：本研究在泛非临床试验注册数据库（PACTR202007465309582）中进行了前瞻性记录（https://pactr.samrc.ac.za/.）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Behavioural Brain Research 医学-行为科学

CiteScore

5.60

自引率

0.00%

发文量

383

审稿时长

61 days

期刊介绍： Behavioural Brain Research is an international, interdisciplinary journal dedicated to the publication of articles in the field of behavioural neuroscience, broadly defined. Contributions from the entire range of disciplines that comprise the neurosciences, behavioural sciences or cognitive sciences are appropriate, as long as the goal is to delineate the neural mechanisms underlying behaviour. Thus, studies may range from neurophysiological, neuroanatomical, neurochemical or neuropharmacological analysis of brain-behaviour relations, including the use of molecular genetic or behavioural genetic approaches, to studies that involve the use of brain imaging techniques, to neuroethological studies. Reports of original research, of major methodological advances, or of novel conceptual approaches are all encouraged. The journal will also consider critical reviews on selected topics.